Regeneron Pharmaceuticals (REGN) Releases Results From EMPOWER-Lung 3 trial

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best NASDAQ Stocks to Buy with Huge Upside Potential. On September 9, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced five-year follow-up results from its phase 3 EMPOWER-Lung 3 trial.

The trial tested Libtayo combined with platinum-based chemotherapy versus chemotherapy alone and was meant for adults with advanced or metastatic non-small cell lung cancer without EGFR, ALK, or ROS1 mutations.

The results showed sustained survival benefits, with patients receiving Libtayo plus chemotherapy showing a 19.4% chance of survival at five years. The survival rate is notable, as it is more than double the 8.8% survival rate of chemotherapy alone. Moreover, the safety remained consistent with earlier reports. The results reinforce Libtayo plus chemotherapy as an effective first-line treatment option for advanced NSCLC.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company that discovers, develops, and commercializes medicines for serious diseases.

While we acknowledge the potential of REGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than REGN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.